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exceeding the FDA label recommendations of ADA 40 mg biweekly, ETN 50 mg 
weekly, and UST 45 mg every 12 weeks. RESULTS: In total, 15,400 PsA patients and 
40,545 PSO patients met the inclusion criteria. The number (proportion) of patients 
receiving increased maintenance doses for PsA was1,603 of 8,908 (18%) for ADA 
and 1,300 of 7,647 (17%) for ETN. The number (proportion) of patients receiving 
increased maintenance doses for PSO was 3,187 of 21,234 (15%) for ADA; 5,201 of 
16,318 (32%) for ETN; and 3,136 of 6,915 (45%) for UST. CONCLUSIONS: A large 
subgroup of patients treated with commonly used biologic agents is maintained 
on increased maintenance doses.
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PerSiStence With FirSt-Line BioLogicS USed in rheUMatoid arthritiS 
in a US Managed care PoPULation
Gu T.1, Shah N.2, Deshpande G.1, Tang D.H.2, Eisenberg D.1, Harrison D.J.2
1HealthCore Inc., Wilmington, DE, USA, 2Amgen Inc., Thousand Oaks, CA, USA
OBJECTIVES: To describe one-year persistence with first-line biologic treatments 
(abatacept [ABA], adalimumab [ADA], certolizumab [CER], etanercept [ETN], 
golimumab [GOL], and infliximab [INF]) in a US managed care population with 
rheumatoid arthritis (RA). METHODS: This is a retrospective cohort study using 
administrative data for individuals in HealthCore Integrated Research Database 
(HIRDSM). The study cohort included patients initiating first-line biologics between 
Jul 2009 and Jan 2013 and was followed for one year since biologic initiation. The 
first biologic used following 6 months of continuous enrollment defined the index 
event. Non-persistence was defined as the absence of persistence, which entails at 
least one > 45-day gap in days of supply on their index agent or a biologic switch. 
Non-persistent patients were further categorized as switching, having a non-index 
biologic claim prior to or following the first gap; restarting, having an index bio-
logic claim after the gap; or discontinuation, no claims for any biologic following 
the gap. RESULTS: A total of 4,937 patients met the eligibility criteria (ABA:290, 
ADA:1,471, CER:132, ETN:2,331, GOL:184, INF:529; mean age:48.4, 76.7% female). 
45.2%, 42.3%, 32.6%, 45.0%, 33.7% and 46.7% patients on ABA, ADA, CER, ETN, GOL, 
and INF were persistent, respectively. GOL patients were the least likely to either 
persist or restart therapy (49.5%), followed by CER (56.1%), ADA (60.4%), ABA (61.4%), 
ETN (63.1%), and INF (64.3%). Switching rate was lowest for ABA (13.1%) and high-
est for GOL (18.5%). Discontinuation rate was lowest for INF (19.7%) and highest for 
GOL (32.1%). CONCLUSIONS: Overall, less than half of patients with RA on first-line 
biologics were persistent during the first year of therapy in this population. As low 
persistence may compromise treatment effectiveness, more research is needed to 
understand the reasons for non-persistence.
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anaLySiS oF etanercePt treatMent PatternS and reiMBUrSeMent 
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OBJECTIVES: To estimate the length of gaps in reimbursement when an etanercept 
patient transitions from private to public plans, and describe their treatment 
patterns and lines of therapy. METHODS: A retrospective cohort of medication 
transaction data (IMS Brogan Lifelink® database) from Ontario and Quebec phar-
macies was analyzed. Patients were eligible if their last etanercept transaction 
from a private plan (index date) was between 01/01/2010 and 06/30/2013 and their 
first transaction from a public plan was within one year from the index date. The 
gaps in reimbursement were the difference between the index date plus days’ 
supply and the date of the first public etanercept transaction. RESULTS: Of 474 
patients included, 432 continued a DMARD or biologic in their public plan and 
397 had at least 1 year of follow-up from their first public claim. Patients were 
50% from Ontario, 40% male. 73% had rheumatoid arthritis (RA) and 70% were < 
65 years. 75% had a gap in reimbursement (median = 19 days). 25% had either 
no gap, or an overlap in dispensed prescriptions, while 9% stopped their therapy 
altogether. Of patients who continued etanercept therapy on a public plan, 45% 
had a gap in coverage that would be considered a clinically meaningful delay in 
treatment (> 21 days). For etanercept patients who continued therapy for at least 
1 year, 71% progressed to etanercept ± DMARD, 5% to another biologic ± DMARD, 
and 23% to a DMARD only as their first line public therapy. CONCLUSIONS: 
A clinically significant number of patients experienced a meaningful gap in 
etanercept coverage which can result in suboptimal clinical outcomes. Over 
20% of patients revert back to DMARD therapy on a public plan even after pre-
viously receiving a biologic. Almost 10% do not continue RA treatment on a 
public plan.
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OBJECTIVES: i) to provide an overview of the new Common Drug Review (CDR) 
evaluative process for SEBs by the Canadian Agency for Drugs and Technologies in 
Health (CADTH); ii) to illustrate the Canadian Drug Expert Committee (CDEC) rec-
ommendation from the first monoclonal antibody SEB (infliximab SEB; Inflectra) 
in Canada and how the recommendation compares with regulatory approval; 
and iii) if possible (depending on timing of listings) to highlight how the public 
reimbursement of infliximab SEB compares with that of the reference infliximab 
(Remicade). METHODS: CDR’s SEB submission procedures were retrieved from 
CADTH’s website in order to delineate its history. The CDR recommendation of 
the infliximab SEB was compared to Health Canada’s approved indications. The 
pan-Canadian Pharmaceutical Alliance website was examined for the status of 
the infliximab SEB for potential negotiation. Formulary listing statuses and public 
reimbursement criteria are to be retrieved from provincial and federal formularies 
OBJECTIVES: To assess clinical characteristics of RA patients considered biosimilar-
infliximab-suitable (when it becomes available) by their physicians, in comparison 
to those who were not considered infliximab-biosimilar-suitable in EU. METHODS: 
A medical chart-review study of RA patients was conducted among physicians 
(primarily rheumatologists) in hospitals/private practices in UK/France/Germany/
Italy/Spain (5EU) to collect de-identified data on patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status; physicians identi-
fied whether patient was biosimilar-infliximab-suitable (yes/no), and if yes, rated 
how likely would they prescribe biosimilar-infliximab to them when the product 
becomes available. Physicians were screened for practice-duration and patient-
volume and recruited from a large panel to be geographically representative. 
Consecutive patients currently on (or discontinued within past-3mo) biologic visit-
ing each center/practice during the screening period were selected for chart abstrac-
tion; analysis compared biosimilar-infliximab-suitable to those who were not (per 
physician judgment), excluding those who previously failed infliximab. RESULTS: 
731 patients (UK:166/France:110/Germany:66/Italy:190/Spain:199) were included 
in the analysis. 260 (36%; UK:47%/France:27%/Germany:38%/Italy:40%/Spain:26%) 
were identified as biosimilar-infliximab-suitable; of these, 58% were rated > = 5 
(scale:7(extremely likely)-1(not at all likely)) regarding likelihood of being prescribed 
biosimilar-infliximab. For biosimilar-infliximab-suitable Yes/No groups, mean age: 
50.5yrs/ 50.9yrs; Female:74% (both-groups); time since diagnosis: 70.2/84.1mo; 
mean # of lines of past biologic/oral-DMARD use: 1.2/1.3. Current drug class usage 
included (biosimilar-infliximab-suitable:Yes/No): biological-DMARD:96%/93%, non-
biological-DMARD:60%/63%, steroids:21%/28%, NSAIDs-COX2-inhibitors:11%/7%, 
NSAIDs- non-COX2-inhibitors:16%/11%, and analgesics:25%/12%. Percentage 
patients with moderate/severe disease (per physician judgment; biosimilar-inf-
liximab-suitable:Yes/No):49%/41%. Among those with available data, recent lab/
disease measures were (biosimilar-infliximab-suitable:Yes/No): ESR(23.3/22.7mm/h) 
and CRP(14.2/8.0mg/dl); HAQ(1.0/1.0), DAS28 (3.2/3.0), VAS(0-10scale; 3.8/3.6), Swollen 
Joint Count(3.2/2.1) and Tender Joint Count(5.3/3.2). CONCLUSIONS: Patients con-
sidered infliximab-biosimilar-suitable (per clinical judgment) had been in care for 
relatively shorter period, had higher disease severity and a lower percentage of them 
used steroids. Physicians were also not readily prepared to prescribe the biosimilar 
to all infliximab-biosimilar-suitable patients. Further scrutiny is warranted to under-
stand the drivers behind physician perception of biosimilar-infliximab-suitability.
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antirheUMatic drUgS (dMardS) on heaLth care coSt and Medication 
eFFectiveneSS
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OBJECTIVES: To examine biologic use, health care costs, and medication effectiveness 
for patients initiating biologic DMARDs before vs. after a 2012 policy change imple-
mentation restricting receipt of adalimumab to patients who had previously failed 
another biologic. METHODS: Patients newly initiating a biologic from 01JAN2011-
30JUN2012, and continuously enrolled for 1 year before and after the initial biologic 
claim (index) were identified from a large geographically diverse US health plan affili-
ated with Optum. Patients with a claim for rheumatoid arthritis (RA), psoriasis, pso-
riatic arthritis, or ankylosing spondylitis were included. Total health care costs were 
examined in the 1-year post-index for all patients. Medication effectiveness at 1-year 
was assessed in patients with RA using a previously validated claims-based algorithm. 
Cost and effectiveness were examined comparing patients initiating a biologic before 
vs. after policy implementation (01JAN2011-30JUN2011 vs. 01JAN2012-30JUN2012). 
Total health care costs were inflation-adjusted using the 2013 CPI, and biologic cost 
was calculated using December 2013 WAC values. RESULTS: Of 46,668 patients treated 
with a biologic from 01JAN2011-30JUN2012, 4,181 met all selection criteria; 1,441 
and 1,330 patients newly initiated a biologic before vs after policy implementation. 
Adalimumab and etanercept accounted for 40.2% and 41.3% of new starts in 2011, 
respectively. In 2012 19.5% and 51.4% initiated adalimumab and etanercept, respec-
tively. The 2011 vs 2012 mean [median] total health care costs were $10,941 [$4,821] 
vs. $10,467 [$4,558] (p= 0.59) and the overall cost of all biologics were $25,328 [$25,361] 
vs. $24,783 [$25,307] (p= 0.26). The percentage of RA patients effectively treated in the 
2011 and 2012 cohorts was 25.6% vs. 25.0%, respectively (p= 0.78). CONCLUSIONS: 
Policy implementation resulted in a noticeable change in the proportion of patients 
treated with adalimumab and etanercept. Patients initiating therapy before and after 
policy implementation experienced similar total health care costs, biologic cost, and 
algorithm-defined medication effectiveness.
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FreqUency oF increaSed Maintenance doSeS oF adaLiMUMaB, 
etanercePt, and UStekinUMaB
Kuznik A.1, Natu A.2, Siper K.2, Auld M.2, Gilra N.2
1Celgene Corporation, Warren, NJ, USA, 2ZS Associates, Princeton, NJ, USA
OBJECTIVES: Psoriasis (PSO) and psoriatic arthritis (PsA) are immune-mediated 
inflammatory diseases. Therapeutic management may include use of biologic 
agents such as adalimumab (ADA), etanercept (ETN), and ustekinumab (UST). In 
clinical practice, patients may receive increased doses during the maintenance 
phase of treatment, exceeding the dosing recommended in FDA labels. The objec-
tive of this study was to assess the proportion of patients treated with ADA or ETN 
for PsA, and ADA, ETN, or UST for PSO who receive an increased maintenance 
dose. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient diag-
noses of PsA or PSO were selected from the Symphony PTD Claims Database if 
their first biologic prescription date (index date) fell between May 2010 and April 
2013. Patients were included if (1) full access was available to all pharmacy claims 
≥ 12 months before and ≥ 12 months after their index date, and (2) they were 
treatment-naive to the agent of interest pre-index. Treatment with a different 
biologic pre-index was not considered a reason for exclusion. Dosing was assessed 
over 12 months post-index. Increased maintenance doses were defined as doses 
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following the publication of the FOCUS trial (p < 0.001). Transfusion rates among 
patients with a minimum hemoglobin value of < 8 g/dL, a concurrent control group, 
were unchanged. Hospital-level variation in transfusion rates declined signifi-
cantly. CONCLUSIONS: The FOCUS trial had a major impact on practice patterns. 
Consistent with the theory that practice variation is due to clinical uncertainty 
about the benefits from alternative approaches to treatment, publication of the 
trial reduced provider-level variation. The policy implication is that the govern-
ment should fund trials of services thought to be ineffective because physicians 
respond to high-quality evidence. In most cases, the expected savings are large 
in relation to the trial costs.
reSPiratory-reLated diSorderS - cLinicaL oUtcoMeS StUdieS
PrS1
tranSFUSion-reLated acUte LUng injUry (traLi) occUrrence aMong 
inPatient Medicaid BeneFiciarieS, Under 65 yearS oF age, aS recorded 
By Large adMiniStrative dataBaSeS dUring 2007-2010
Menis M.1, Forshee R.A.1, McKean S.2, Warnock R.2, Verma S.2, Izurieta H.S.1, Mintz P.D.1, 
Worrall C.M.3, Kelman J.A.4, Anderson S.A.1
1FDA, Silver Spring, MD, USA, 2Acumen LLC, Burlingame, CA, USA, 3CMS, Baltimore, MD, USA, 
4CMS, Washington DC, DC, USA
OBJECTIVES: Transfusion-Related Acute Lung Injury (TRALI) is a serious transfu-
sion complication resulting in pulmonary edema and respiratory failure. The study 
objectives were to assess TRALI occurrence and potential risk factors among inpa-
tient Medicaid beneficiaries under 65 years of age, during 2007-2010. METHODS: This 
retrospective claims-based study utilized large Medicaid databases. Transfusions 
were identified by recorded procedure and revenue center codes, while TRALI was 
ascertained via ICD-9-CM diagnosis code. Revenue center units were used to quan-
tify blood use. Study evaluated TRALI rates (per 100,000 transfusion stays) among 
Medicaid beneficiaries, overall and by year, age, sex, race, number of units and 
blood components transfused. RESULTS: Of 1,123,113 inpatient transfusion stays 
for Medicaid beneficiaries during 2007-2010, 162 had TRALI diagnosis recorded, an 
overall rate of 14.42 per 100,000 stays. Annual TRALI rates were 12.70, 10.67, 16.60, 
and 18.14, respectively. TRALI rates for ages 0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 
and 60-64 were 5.15, 13.41, 17.22, 19.59, 19.44, 13.66, and 10.54. Rates for females 
and males were 12.78 and 17.28, whereas for whites and non-whites were 15.55 
and 13.45. TRALI rates by number of units were: 9.56 for 1 unit, 7.72 for 2-4 units, 
17.70 for 5-9 units, and 62.12 for > 9 units. Rates by blood component groups were: 
13.86 for RBCs only, 4.93 for plasma only, 23.22 for platelets only, 37.37 for platelets 
and plasma, 56.02 for RBCs and plasma, 43.12 for RBCs and platelets, and 74.75 for 
RBCs, plasma, and platelets. CONCLUSIONS: This is the first and largest-to-date 
claims-based TRALI study among Medicaid beneficiaries. The results show a possible 
trend of increasing TRALI occurrence over time. The findings also suggest that TRALI 
rates vary by age, sex, race, number of units, and blood components transfused, with 
highest rates for stays with > 9 units transfused and for stays with RBCs transfused 
in combination with plasma and platelets.
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Long-acting BronchodiLatorS and riSk oF adverSe cardiovaScULar 
eventS in chronic oBStrUctive PULMonary diSeaSe: a FocUSed 
criticaL revieW
Tao S.1, Kirsch E.1, Yeomans K.1, Sigler C.2
1UBC: An Express Scripts Company, Dorval, QC, Canada, 2UBC: An Express Scripts Company, Blue 
Bell, PA, USA
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is one of the lead-
ing causes of morbidity and mortality worldwide. Long-acting bronchodilators 
(LABs) are the mainstay of pharmacological maintenance therapy for COPD. 
However, the possibility that use of LABs may lead to risk of cardiovascular 
events remains debated. The objective is to provide a critical review of meth-
odologies employed to evaluate risk of cardiovascular events in patients with 
COPD using LABs. METHODS: A targeted search was conducted in PubMed to 
identify all original published research reporting adverse cardiovascular events 
from clinical trials and observational studies. The search was limited to English 
language, but not restricted by publication date. Selected abstracts were reviewed 
for study population, treatment, follow-up duration, study design, and cardiovas-
cular events. RESULTS: The search returned 131 citations, of which 19 reported 
results from original research. Among them, 10 studies (53%) were clinical trials 
and 9 (47%) were observational studies. For the clinical trials, sample sizes ranged 
from 204 to 6,184 patients; follow-up duration was 14 days to 4 years. For the 
observational studies, 6 (67%) were nested case-control studies, 2 (22%) cohort 
studies, 1 (11%) self-controlled case series study; sample sizes ranged from 1,043 to 
352,631 patients; follow-up duration was 52 weeks to 13 years. The most frequently 
reported cardiovascular events included arrhythmias, stroke, angina, myocardial 
infarction and cardiovascular death. While none of the clinical trials showed a 
statistically significant association between the use of LABs and increased risk of 
cardiovascular events, 5 observational studies did. CONCLUSIONS: The contro-
versy continues regarding the use of LABs and their cardiovascular safety. Short 
follow-up duration and exclusion of patients with previous history of cardiovas-
cular events are the main limitations to clinical trials, while observational studies 
may be limited by residual confounding by disease severity and immeasurable 
time bias. A well-designed observational study is warranted.
PrS3
MortaLity and readMiSSion in MechanicaLLy ventiLated PatientS 
With PneUMonia
Hansen R.N.1, Black D.J.1, Joish V.N.2, Spilsbury-Cantalupo M.2, Sullivan S.D.1
1University of Washington School of Pharmacy, Seattle, WA, USA, 2Bayer Healthcare 
Pharmaceuticals, Whippany, NJ, USA
and compared to those for the reference infliximab. RESULTS: The current CDR 
SEB submission procedure represents a significant deviation from that for non-SEB 
products. The CDR Recommendation for the infliximab SEB included comments 
related to the clinical evidence demonstrating similar efficacy and safety to the 
reference infliximab. The indications recommended for reimbursement by the 
CDR are also consistent with those of Health Canada. We expect that infliximab 
SEB will undergo pan-Canadian Pharmaceutical Alliance negotiation, which would 
be followed by reimbursement decisions by the public plans. CONCLUSIONS: The 
first monoclonal antibody SEB received a positive CDR recommendation, in part, 
based on comparative clinical data demonstrating similar efficacy and safety. 
Non-monoclonal antibody SEBs lacking comparative phase III clinical studies have 
recently been approved by the European Medicines Agency. The CDR’s assessments 
of these products will be of great interest.
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iMPact oF overWeight/oBeSity on arthritiS–attriBUtaBLe BUrden 
and heaLth–reLated qUaLity oF LiFe aMong adULtS With arthritiS
Khanna R., Joshi N., Shah R.
University of Mississippi, University, MS, USA
OBJECTIVES: The incremental impact of overweight/obesity on the chronic disease 
burden and health–related quality of life (HRQOL) among individuals with arthri-
tis is not fully understood. This study aimed to determine the additional influ-
ence of overweight/obesity on arthritis–attributable burden (joint limitation, work 
limitation, social activity limitation, and joint pain) and HRQOL (general health 
status, physical HRQOL, mental HRQOL, activity limitations) among a representa-
tive national sample of adults with arthritis in the United States (US). METHODS: 
This study involved a cross–sectional, retrospective analyses of the 2013 Behavioral 
Risk Factor Surveillance System (BRFSS) data. The study sample included adults 
(≥ 18 years) with arthritis and related disorders. Based on their body mass index 
(BMI), participants were categorized into six groups: underweight, normal weight, 
overweight, and class I/II/III obese. Multivariable logistic regression models were 
fitted to assess the study objectives. Data analyses were conducted using SASv9.3 
(PROC SURVEY) procedures. RESULTS: The study sample included 157,113 adults 
with arthritis, of which 138,707 (88.2%) were also overweight/obese. Class III obese 
adults with arthritis had higher odds of joint limitations (Odds ratio [OR] = 1.439), 
work limitations (OR = 1.144), social activity limitations (OR = 1.368), and joint pain 
(OR = 1.099) compared to normal weight adults. Class III obese adults also had 
greater odds of poor physical HRQOL (OR = 1.141), mental HRQOL (OR = 1.273), and 
activity limitations (OR = 1.233) in comparison to adults with normal weight. A simi-
lar pattern was observed when overweight/class I/II obese adults with arthritis were 
compared to normal weight adults with arthritis. CONCLUSIONS: Study results 
highlight a significant negative impact of overweight/obesity on arthritis–attribut-
able burden and HRQOL among individuals with arthritis. Weight management is 
critical towards improving HRQOL and alleviating the burden of arthritis. Providers 
should emphasize weight management during their interaction with adults with 
arthritis.
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aSSeSSMent oF oSteoPorSiS knoWLedge and PercePtion aMong 
FeMaLe UniverSity StUdentS in qUetta, PakiStan
ul Haq N.1, Tahir M.1, Iqbal Q.1, Naseem A.1, Mohammd S.1, Ahmed N.1, Azhar S.A.2
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OBJECTIVES: The present study intended to investigate knowledge about osteo-
porosis among female students of university in Quetta., Pakistan. METHODS: A 
Cross-sectional study was used to assessed the knowledge by a pre-validated self-
administered questionnaire containing 20 disease related questions. Convenience 
sampling technique was used for data collection. Descriptive analysis was used 
to demonstrate the characteristics of the study population. Inferential statistics 
(Mann-Whitney U test and Kruskal Wallis tests, p< 0.05) were used to assess 
the significance among study variables. RESULTS: Out of 162 female students, 
153(81.5%) were single and were science faculty students 123 (75.9%) with the 
majority of the age group of less than 24 years. Mean age of the study partici-
pants was 21.91±1.74years. 134 (82.7%) have not been previously diagnosed of 
bone related problem or osteoporosis. The mean score of knowledge was 13.01±2.9 
(max 20). Department of study and living status were significantly associated with 
knowledge scores. CONCLUSIONS: The study concluded that females of science 
faculty and who had a better life style had better understanding of the disease, 
osteoporosis, but they need to know the availability of treatment for this disease 
in Pakistan and it is also necessary for them to know more about some specific 
risk factors.
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the iMPact oF negative triaL reSULtS on the USe oF BLood 
tranSFUSionS
Howard D.H.
Emory University, Atlanta, GA, USA
OBJECTIVES: Clinical trials that find that widely-used treatments do not improve 
patient outcomes can reduce costs, but only if physicians modify their practice 
patterns accordingly. The FOCUS trial, which was published in the New England 
Journal of Medicine in late 2011, found that post-operative red blood cell trans-
fusions do not improve outcomes among patients undergoing surgery for hip 
fracture with hemoglobin levels over 8 g/dL. METHODS: We studied transfusion 
trends in 6,437 patients who underwent surgery to repair a hip fracture between 
2009 and 2013 at 18 US community hospitals. The hospitals are unaffiliated but 
report data to the Institute for Health Metrics. The data include diagnosis and pro-
cedure codes, hemoglobin values, and red blood cell transfusions. RESULTS: Age-, 
sex-, and comorbidity-adjusted transfusion rates among patients with a minimum 
post-operative hemoglobin value of 8 to 10 g/dL declined by 19 percentage points 
